Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Talis Biomedical Corporation (TLIS) had Return on Equity of -89.72% for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$2.13M |
|
$-62.01M |
|
$0.04M |
|
$2.09M |
|
$68.95M |
|
$-66.81M |
|
$4.81M |
|
$-62.01M |
|
$-62.01M |
|
$-62.01M |
|
$-62.01M |
|
$-62.01M |
|
$-62.01M |
|
$-66.81M |
|
$-66.05M |
|
1.82M |
|
1.82M |
|
$-34.12 |
|
$-34.12 |
|
| Balance Sheet Financials | |
$77.68M |
|
$3.03M |
|
$16.99M |
|
$94.67M |
|
$8.77M |
|
-- |
|
$16.79M |
|
$25.56M |
|
$69.11M |
|
$69.12M |
|
$69.12M |
|
1.82M |
|
| Cash Flow Statement Financials | |
$-53.24M |
|
$-0.49M |
|
$0.03M |
|
$131.97M |
|
$78.27M |
|
$-53.69M |
|
$4.35M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.86 |
|
-- |
|
-- |
|
-- |
|
-- |
|
98.08% |
|
-3130.97% |
|
-3130.97% |
|
-3094.89% |
|
-2905.67% |
|
-2905.67% |
|
$-53.73M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
42.68 |
|
8.55 |
|
|
Return on Equity |
-89.72% |
-89.71% |
|
-65.50% |
|
-89.71% |
|
$37.93 |
|
$-29.56 |
|
$-29.29 |
|